Search
Tegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalTegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by … It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327].
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalTralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the … [A242432] It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis.
Categories: Agents for Dermatitis, Excluding CorticosteroidsDengue virus serotype 4
go.drugbank.com/drugs/DB22667Approved[A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease. … [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Brexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalThe development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before [F4066]. … March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … [L39125] It is being investigated for other inflammatory skin conditions.
Categories: Agents for Dermatitis, Excluding CorticosteroidsPyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedPyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900]. … Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis
Mixtures: Heartgard Plus Chewable Tablet for Dogs - Up to 25 lbs, Heartgard Plus Chewable Tablet for Dogs - 26 - 50 lbsNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalBy blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2. … [L43747] On December 12, 2025, the FDA expanded niraparib and abiraterone acetate (AKEEGA) with prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer
Bordetella pertussis pertactin antigen
go.drugbank.com/drugs/DB10789ApprovedInvestigationalBordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis [A31248].
Mixtures: , Suspension for Injection, ADACEL SUSPENSION FOR INJECTIONSulfoxone
go.drugbank.com/drugs/DB01145ApprovedSulfoxone is a water-soluble sulfone used as an antileprosy drug. It has been used with limited success in the treatment of dermatitis herpetiformis.
Categories: Drugs for Treatment of Lepra, Antiinfectives for Systemic UsePravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigationalIt was the first statin administered as the active form and not as a prodrug.[T274] This drug was developed by Sankyo Co. … Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia